Alzheimer’s Disease/Dementia News

The FDA granted breakthrough therapy designation for two investigational antibody therapies in Alzheimer’s disease. Lecanemab is an anti-amyloid beta protofibril antibody and donanemab targets N3pG, a modified form of beta amyloid.

June is Alzheimer’s and Brain Awareness Month, an observance recognized each year by the CDC and other organizations to raise awareness of Alzheimer’s disease and other dementias.

Gantenerumab decreased molecular markers of disease, but did not demonstrate a cognitive benefit, in patients with dominantly inherited Alzheimer’s disease, according to results from a phase 2/3 trial.

Statin therapy was not associated with dementia, mild cognitive impairment and/or any of its subclassifications, according to a secondary analysis of the ASPREE trial of aspirin therapy among older adults.

Obsessive-compulsive disorder independently increased risk for subsequent dementia, including Alzheimer’s disease and vascular dementia, according to results of a nationwide longitudinal study published in Journal of Clinical Psychiatry.

The FDA’s decision to approve Aduhelm represented one of the agency’s “most controversial [approvals] ever,” according to a piece published in the Ideas and Opinions section of Annals of Internal Medicine.

The FDA today granted accelerated approval for Aduhelm, the first new treatment to be approved for Alzheimer’s disease since 2003.

Anticholinergic medication burden is substantial among individuals with schizophrenia, according to results of a cross-sectional data analysis published in American Journal of Psychiatry.

The adoption of at least three healthy behaviors was associated with reduced risk for dementia among individuals with familial dementia, a speaker reported.

Psychiatric conditions were associated with a younger age at onset of Alzheimer’s disease, and age differences only grew with each additional psychiatric diagnosis, researchers reported.